Otsuka Holdings Co., Ltd. – Unsponsored ADR (OTCMKTS:OTSKY – Get Free Report) gapped up before the market opened on Friday. The stock had previously closed at $37.96, but opened at $38.9670. Otsuka shares last traded at $39.2050, with a volume of 971 shares trading hands.
Wall Street Analyst Weigh In
Separately, Zacks Research lowered shares of Otsuka from a “strong-buy” rating to a “hold” rating in a research note on Monday, November 9th. One analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold”.
View Our Latest Analysis on Otsuka
Otsuka Price Performance
The company has a debt-to-equity ratio of 0.05, a current ratio of 2.21 and a quick ratio of 1.65. The stock has a market capitalization of $41.75 billion, a price-to-earnings ratio of 16.68, a price-to-earnings-growth ratio of 2.74 and a beta of 0.08. The company has a 50-day simple moving average of $37.31 and a two-hundred day simple moving average of $35.44.
Otsuka (OTCMKTS:OTSKY – Get Free Report) last announced its quarterly earnings results on Friday, October 30th. The company reported $0.64 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.59 by $0.05. Otsuka had a net margin of 14.36% and a return on equity of 11.90%. The company had revenue of $4.51 billion during the quarter, compared to the consensus estimate of $4.42 billion. On average, equities research analysts predict that Otsuka Holdings Co., Ltd. – Unsponsored ADR will post 2.21 earnings per share for the current year.
Otsuka Company Profile
Otsuka Holdings Co., Ltd. is a Japan-based holding company whose businesses focus primarily on pharmaceuticals and nutraceuticals. Its group companies research, develop, manufacture, and market prescription medicines, consumer health products, and medical devices. Otsuka’s pharmaceutical portfolio includes treatments across areas such as mental health, kidney disease, and oncology. Its nutraceutical business offers products including Pocari Sweat and CalorieMate, alongside other nutrition and wellness products.
Featured Stories
- Five stocks we like better than Otsuka
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
- Cracks in the Crockery? Williams-Sonoma Insiders Sell Shares
Receive News & Ratings for Otsuka Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Otsuka and related companies with MarketBeat.com's FREE daily email newsletter.
